In most human somatic cells, the lack of telomerase activity results in progressive telomere shortening during each cell division. Eventually, DNA damage responses triggered by critically short telomeres induce an irreversible cell cycle arrest termed replicative senescence. However, the cellular responses of human pluripotent stem cells to telomere uncapping remain unknown. We generated telomerase knockout human embryonic stem (ES) cells through gene targeting. Telomerase inactivation in ES cells results in progressive telomere shortening. Telomere DNA damage in ES cells and neural progenitor cells induces rapid apoptosis when telomeres are uncapped, in contrast to fibroblast cells that enter a state of replicative senescence. Significantly, telomerase inactivation limits the proliferation capacity of human ES cells without affecting their pluripotency. By targeting telomerase activity, we can functionally separate the two unique properties of human pluripotent stem cells, namely unlimited self-renewal and pluripotency. We show that the potential of ES cells to form teratomas in vivo is dictated by their telomere length. By controlling telomere length of ES cells through telomerase inactivation, we can inhibit teratoma formation and potentially improve the safety of cell therapies involving terminally differentiated cells as well as specific progenitor cells that do not require sustained cellular proliferation in vivo, and thus sustained telomerase activity. STEM CELLS 2016; 00:000-000
INTRODUCTION
Human chromosome ends are capped by telomeres that contain long six-nucleotide DNA repeats 5 0 -TTAGGG-3 with single stranded 3 0 G-rich overhangs [1] . The telomeric DNA repeats are bound by shelterin protein complexes consisting of TRF1, TRF2, RAP1, TIN2, TPP1, and POT1 that distinguish naturally occurring chromosomal ends from DNA double-strand breaks. Therefore, telomeres are essential for cell genomic stability. Telomeric repeat sequences are synthesized by telomerase, a reverse transcriptase. The human core telomerase contains at least two essential subunits, the protein subunit, hTERT, and the RNA subunit, hTR, [2, 3] . While hTR is widely expressed, hTERT and, consequently, telomerase activity, is barely detected in most human adult somatic tissues, except germ cells and some stem cells [2] [3] [4] [5] [6] . Because of the lack of telomerase activity in somatic cells, about 50-200 bp of telomeric DNA repeats are lost during each cell division [7, 8] . Progressive telomere shortening may function as an internal clock that determines the replicative capacity of normal human somatic cells [9] . When telomeres shorten to a critical limit, they become Neuroscience Academic Clinical Programme, h uncapped. This triggers ATM-and/or ATR-dependent DNA damage signaling cascades. Through the downstream transducer kinases CHK2 and CHK1, the uncapped chromosome ends are marked by proteins involved in DNA damage response, such as 53BP1, NBS1 and g-H2AX, and form cytologically distinct telomere dysfunction-induced foci (TIFs) [10] . This is different from telomere-associated foci that can arise from anywhere in the telomere [11, 12] . As few as five dysfunctional telomeres are sufficient to trigger irreversible cell cycle arrest, termed replicative senescence, in primary human fibroblast cells [13] [14] [15] . Such cells at senescent state are metabolically active and arrest at G1 phase. They show enlarged cell morphology, b-galactosidase induction, as well as a senescence-associated secretory phenotype [16] . The induction of replicative senescence is dependent on functional p53 and pRB, as inactivation of these two pathways leads to the escape of senescence [17] . One p53 target-p21 is upregulated during replicative senescence and plays a pivotal role in cell cycle arrest at the G1 phase, as p21 inactivation can postpone the onset of senescence [18] . Previous studies proposed that progressive telomere shortening in normal human somatic cells leads to an intermediate-state telomere structure in which the chromosome end triggers the DNA damage response, while preventing the occurrence of chromosome end-to-end fusion [15, 19] . Such a model predicts persistent activation of the DNA damage response, since dysfunctional telomeres are irreparable [11, 12] .
Recent studies link telomere dysfunction to diverse degenerative diseases and premature aging. While telomere length in embryonic stem (ES) cells and germ cells is sustained, the telomerase activity in tissue-specific progenitor/stem cells is not sufficient for complete telomere maintenance [20] . As a result, the telomere length in tissue-specific progenitor/stem cells shortens progressively. This length decrease eventually leads to telomere uncapping and induction of ATM-and/or ATR-dependent DNA damage signaling cascades, which limit the proliferation capacity of tissue-specific progenitor/stem cells [21] . Consistent with these findings, heterozygous mutations in dyskerin, hTR, and hTERT, as well as other telomere maintenance genes, are found in patients with premature aging suffering from conditions, such as dyskeratosis congenita, aplastic anemia, myelodysplastic syndrome, and idiopathic pulmonary fibrosis [22] . The telomerase knockout mouse model facilitates investigations into telomere dysfunctionmediated diseases and shows remarkable similarity to the human disease phenotypes [23] [24] [25] . However, the cellular responses of human stem cells and progenitor cells to dysfunctional telomeres have not been characterized in detail.
Cell types respond distinctively to various types of DNA damage ranging from cell cycle arrest and senescence to apoptosis. ES cells and induced pluripotent stem (iPS) cells are particularly sensitive to DNA damage-induced apoptosis [26] [27] [28] [29] . Such a mechanism may eliminate damaged cells to prevent compromising genomic integrity and tumorigenicity in humans. Several distinct properties of ES cells and iPS cells may regulate pluripotent stem cell responses to DNA damage: (a) differential activation of p53 transcriptional targets and p53 interacting cytoplasmic partners, (b) high mitochondria priming or readiness for apoptosis due to the balance between pro-apoptotic and anti-apoptotic proteins shifting closer to the apoptotic threshold [30] , and (c) an abbreviated G1 phase [31] . Conversely, adult stem cells are more resistant to DNA damage-induced apoptosis, although such resistance may compromise genomic instability, when DNA damage-induced mutations are not properly repaired [32] . Understanding how pluripotent and adult stem cells regulate cellular responses to DNA damage, as well as their biological roles in vivo, remains limited. Previous studies determined that within two days following induction of human ES cell differentiation through embryoid body (EB) formation, partially differentiated cells become resistant against DNA damage-induced apoptosis [31] .
To investigate the cellular responses of ES and progenitor cells to telomere dysfunction, we engineered telomerase knockout human ES cells using gene targeting. We find that telomerase-null ES cells retain their pluripotency, and their potential to form teratomas in vivo is limited by their telomere length. When telomeres are shortened to a critical limit, the telomerase-null ES cells with dysfunctional telomeres undergo apoptosis rather than permanent cell cycle arrest (senescence). Telomere dysfunction also induces cellular apoptosis in partially differentiated neural progenitor cells (NPCs) distinct from the cellular responses caused by treatment with DNA damaging reagents. Therefore, by inactivating telomerase, an intrinsic pathway that is naturally silenced during cellular differentiation, we can limit the self-renewal capacity of ES cells and NPCs without affecting their pluripotency both in vitro and in vivo. Manipulating telomere length in telomerasenull ES cells permits a balance between cell proliferation capacity and tumor formation prevention. This strategy provides a novel solution that may reduce, if not eliminate, the tumorigenicity of stem cells during cell therapy.
MATERIALS AND METHODS

CRISPR and Paired Zinc Finger Nucleases
The exon 1 of human hTERT gene was subjected to potential sgRNA target search using the online software created by Feng Zhang's group (http://tools.genome-engineering.org) [33] . The very top hits were chosen and used for the experiments hence described. The zinc finger nucleases (ZFNs) expression plasmids were ordered from Sigma-Aldrich, St. Louis, Missouri, https:// www.sigmaaldrich.com (Cat# CSTZFN-1KT-hTERT).
Maintenance of H1 Human ES Cell Culture
Feeder-independent human H1 and WA018 ES cells from WiCell were grown on matrigel (BD Biosciences, Franklin Lakes, New Jersey, http://www.bd.com)-coated cell culture dishes using mTeSR1 culture medium (StemCell Technologies, Vancouver, Canada, http://www.stemcell.com). When the cells reached 80%-90% confluence, they were passaged using Dispase, and split 1:6 to 1:12 onto new matrigel-coated cell culture dishes.
Gene Targeting Using Neon Transfection System
The gene-targeting procedure was adapted from previously published protocols [34] . WA018 and H1 human ES cells were grown to 80%-90% confluence. The cells were then harvested using Accutase, and the cell number counted. The cells were washed once with 1xPBS before resuspension in Resuspension buffer (R) at 1 x 10 7 cells/ml. For every 1 x 10 7 cells in 1 ml of Resuspension buffer, 25 lg of each pCas9(D10A)-green fluorescent protein (GFP)-sgRNA plasmid was mixed with WA018 0 -PGK-DTA(DZFN) targeting plasmid were added and mixed with H1 cells well before electroporation. For electroporation, 100 ll of the cell suspension in Resuspension buffer was electroporated using a 100 ll Neon pipette in a Neon tube containing 3 ml of Electrolytic Buffer (E2). The electroporation conditions are as follow: Pulse, V 1050, MS 30, Number 2. After the electroporation, the cells were plated onto matrigelcoated 10 cm dish in 6 ml of mTeSR1 containing 10 lM Y-27632 (Rock inhibitor). About 5-6 x 10 6 cells were plated onto one 10 cm dish. The cells were maintained in mTeSR1, and the medium was changed every day.
Screening of hTERT Knockout Clones in WA018
At 48 hours after electroporation, the GFP positive cells were sorted and seeded on matrigel-coated plate in mTeSR1 containing 10 lM Y-27632 to allow the emerging of single cell colonies. Fluorescent PCR-capillary gel electrophoresis was then utilized to screen for colonies with biallelic deletion in hTERT coding region [35] .
Screening of G418-Resistant Targeted H1 ES Cell Clones
At 48 hours after electroporation, mTeSR1 containing 50 lg/ ml G418 was added to select for G418-resistant clones. The cells were maintained in mTeSR1 containing 50 lg/ml G418 for about 12 days before the colonies were big enough for picking. When the G418-resistant colonies reached about 3-4 mm in size, the individual G418-resistant clones on the 10 cm dish were then picked using sterile P200 pipette tip and transferred onto two new wells of matrigel-coated 96-well plate. The colonies grew for 2-3 days prior to screening using PCR, as previously described [36] .
Genomic DNA Extraction and Southern Blotting
Genomic DNA was extracted using Gentra Puregene Genomic DNA Purification Kit (Qiagen, Hilden, Germany, https://www. qiagen.com). Southern blots for detection of targeted genomic insertions were performed as previously described [37] . For telomerase activity analysis, telomeric repeat amplification protocol (TRAP) assay was performed as previously described [4] . For telomere length measurement, the genomic DNA was digested with HphI and MnlI at 378C for 16 hours. The DNA blot was hybridized with 32 P-labeled (TTAGGG) 6 oligonucleotides as previously described [38] .
FLP Pop-Out of PGK-Neo Selection Cassette
For FLP pop-out of PGK-Neo cassette, the cells were transiently transfected with pCAG-Flpe:GFP plasmid using Neon transfection system (as described above). The cells were maintained in mTeSR1 containing 10 lM Y-27632 for 24 hours, and GFP-positive cells were then sorted out and collected using FACS. The cells were then seeded at low density of 200-500 cells/well in a 6-well dish to allow single ES cell to form individual colony. When the colonies grew to about 3-4 mm in diameter, they were transferred to a 96-well dish and subjected to PCR diagnosis for the excision of PGK-Neo cassette.
Cre Pop-Out of hTERT Alleles
For Cre pop-out of hTERT exon 1 and exon 2, hTERT 1/loxP and hTERT loxP/loxP cells were transiently transfected with pCre-IRESmCherry plasmid using Neon transfection system (as described above). The cells were maintained in mTeSR1 containing 10 lM Y-27632 for 24 hours, the mCherry-positive cells were sorted and collected using FACS. The cells were then seeded at low density of 200-500 cells/well on a 6-well dish to allow single ES cells to form individual colonies. When the colonies grew to about 3-4 mm in diameter, they were transferred to a 96-well dish and subject to PCR diagnosis for the excision of hTERT exon 1 and exon 2.
Reset of Telomere Length in Telomerase Inducible Knockout ES Cells by Transient Overexpression of hTERT
To reset telomere lentgth in telomerase inducible knockout ES cells, an episomal vector expressing hTERT-IRES-GFP was transiently transfected into the hTERT loxP/loxP ES cells, after which the GFP-positive cells were FACS sorted and single cell colonies were isolated. No integration of the hTERT-IRES-GFP expression vector was detected as the single cell-derived colonies were negative for GFP expression. No integration of hTERT-IRES-GFP expression vector was further supported by the lack of telomerase activity and gradual telomere shortening in these cells upon Cre-induced deletion of endogenous hTERT.
Cell Proliferation Assay-CellTiter-Glo
Cells were seeded onto 96-well plate at a density of 1000 cells/well and cultured over a period of 7 days to monitor cell proliferation using ATP assay (CellTiter-Glo Luminescent Cell Viability Assay, Promega, Fitchburg, Wisconsin, https://www. promega.com). Luminescence was measured on a microplate reader (Infinite 200,Tecan, Mannedorf, Switzerland, www. tecan.com) every 24 hours.
Cell Proliferation assay-EdU Labeling Assay
Cell proliferation was detected through the incorporation of 10 lM EdU within an hour using Click-iT EdU Alexa Fluor 488 Imaging Kit (Thermo Fisher Scientific, Waltham, Massachusetts, www. thermofisher.com). Immunofluorescence staining was done in accordance with the protocol provided by the manufacturer.
Cell Cycle Analysis
Cells were harvested by Accutase, washed, and fixed in icecold 70% ethanol followed by propidium iodide (PI) staining with RNase A treatment. Cell cycle profiles were acquired on flow cytometer MACSQuant VYB (Miltenyi Biotec, Bergisch Gladbach, Germany, http://www.miltenyibiotec.com) and analyzed using ModFit LT.
Apoptosis Assay
Cells were harvested by Accutase, washed once with PBS and stained with 7-AAD and Annexin V (BD Biosciences, Franklin Lakes, New Jersey, http://www.bd.com) for 15 minutes at room temperature in the dark. Cytohistofluorescence data were acquired on flow cytometer BD LSRFortessa (BD Biosciences, Franklin Lakes, New Jersey, http://www.bd.com) and analyzed using FlowJo (Tree Star, Ashland, Oregon, www.flowjo.com).
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Cellular Senescence Assay
The cellular senescence was analyzed using a b-galactosidase staining kit (Cell Signaling Technology, Danvers, Massachusetts, http://www.cellsignal.com) according to the protocol provided.
Microarray Data and Pathway Enrichment Analysis
Total RNA was extracted using NucleoSpin RNA extraction kit (Macherey-Nagel, Duren, Germany, www.mn-net.com) with oncolumn DNase digestion. Gene expression analysis was performed on GeneChip PrimeView human gene expression array (Affymetrix, Santa Clara, California, http://www.affymetrix.com).
Background-adjusted, quantile-normalized gene expression summaries for Affymetrix PrimeView chip data were generated via the Robust Multichip Average method [39] . Genes with a maximum average group expression of 50units were retained for downstream analysis. Detection of the major sources of variation (including sample outliers) was accomplished by principal components analysis (PCA) based on covariances (Partek Genomics Suite, v6.6). Differentially expressed genes were identified via analysis of variance, coupled with planned contrasts between relevant groups (Partek Genomics Suite, v6.6). The number of statistically significant differentially expressed genes was controlled by the false discovery rate [40] . Pathway enrichment analysis was conducted via the Gene Set Enrichment Analysis (GSEA) method [41] by comparing gene expression profiles of the relevant groups against the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway repository available from the Molecular Signature Database (MSigDB) [42] . Pathways with a false discovery rate 5% were considered to be statistically significant.
Formation of EB and Induction of Spontaneous Differentiation
Embryoid bodies were formed by plating Accutase-treated single-cell suspension onto low-adherence dishes in human ES cell culture medium. For spontaneous differentiation, 7 to 10-day old EBs were used according to previously established protocol [43] . In brief, the EBs (about 5-10) from human ES cells were transferred onto gelatin-coated 24-well plate and differentiated in DMEM 1 10% fetal bovine serum (FBS) for 1-2 weeks.
Neural Induction, Neuronal and Astrocytes Differentiation
Neural induction of H1 ES cells was carried out using a previously established protocol [44] . Briefly, hTERT 1/1 and hTERT 2/2 ES cells were cultured in mTeSR1 medium. When the ES cell cultures reached 20% confluence, mTeSR1 medium was removed and replaced with neural induction media containing DMEM/F12: Neurobasal (1:1), 1xN2, 1xB27, 1% Glutmax, 5 lg/mL BSA, 4 lM CHIR99021 (Cellagentech, San Diego, California, http:// www.cellagentech.com), 3 lM SB431542 (Cellagentech), 0.1 lM Compound E (g-Secretase Inhibitor XXI, Millipore Darmstadt, Germany, http://www.emdmillipore.com), 10 ng/mL hLIF (Millipore, Darmstadt, Germany, http://www.emdmillipore.com) for 7 days. The culture was then split 1:3 for the next six passages using Accutase, and the cells were cultured in human NPCs maintenance media containing DMEM/F12: Neurobasal (1:1), 1xN2, 1xB27, 1% Glutmax, 5 lg/mL BSA, 3 lM CHIR99021, 2 lM SB431542, 10 ng/mL hLIF on matrigel-coated plates. After six passages, the cells were split 1:10 regularly.
The human NPCs neuronal differentiation assay was performed by plating 5 x 10 4 cells/well on laminin-(378C, 4 hours) coated 24-well plates in neural differentiation media containing DMEM/F12: Neurobasal (1:1), 1xN2, 1xB27, 1% Glutmax on pLL (48C, overnight). After 3 days, 10 ng/mL BDNF and 10 ng/mL GDNF were added to the media every other day and cultured for another 11 days.
The human NPC to astrocyte differentiation assay was performed by plating 8 x 10 4 cells/well onto 1% Glutmax on matrigel-coated 24-well plates in neural differentiation media containing DMEM/F12: Neurobasal (1:1), 1xN2, 1% FBS.
Teratoma Formation Assay
For the teratoma assay, ES cells were harvested using Dispase, washed with 1xPBS, and resuspended in 30% matrigel (BD Biosciences, Franklin Lakes, New Jersey, http://www.bd.com). About 1 x 10 6 cells (100 ll) were injected subcutaneously into NSG mice (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ) in the dorsolateral area bilaterally as previously described [45] . About 8-9 weeks after injection, the mice were sacrificed, and the tumors were harvested.
Transplantation and Histology
Immunodeficient mice (SCID, NOD.CB17-Prkdc scid /NcrCrl) (n 5 5) were anaesthetized with Ketamine (85 mg/kg) plus Xylazine (10 mg/kg) and fixed in a Stoelting stereotaxic apparatus. A small hole was drilled in the skull above the intended injection sites and a syringe (1 ll, Hamilton) containing 1 ll Accutasedissociated human ES cells (5 3 10 4 cells per ll) in PBS (pH 7.4) was lowered into the striatum at 0.5 mm posterior to bregma, 2.0 mm lateral to midline, 3.2 mm ventral to dura. At 4, 8, or 16 weeks after transplantation, animals were deeply anaesthetized and perfused transcardially with 50 ml of saline, followed by 100 ml of 4% paraformaldehyde for 30 minutes. The 40 mm coronal sections were cut using a cryostat, and serial sections were transferred to individual wells of a 24-well tissue culture dish. Sections were incubated in blocking solution (5% normal goat serum and 0.1% Triton X-100 in TBS) for 1 hour. Subsequently, primary antibody (mouse anti-Human Nuclei, 1:500, Abcam; goat anti-DCX, 1: 500, Santa Cruz Biotechnology, Inc. Dallas, Texas, http://www.scbt.com; mouse anti-MAP2, 1:1,000, Sigma-Aldrich, St. Louis, Missouri, https://www.sigmaaldrich.com; mouse antiNeuN, 1:500, Abcam, Cambridge, United Kingdom, www.abcam. com; mouse anti-GFAP, 1:1,000, Millipore, Darmstadt, Germany, http://www.emdmillipore.com) in blocking solution was added to the sections and incubated overnight at 48C. After three TBS washes, sections were incubated with Alexa Fluor-conjugated secondary antibody solution for 2 hours at room temperature. Nuclei were visualized by DAPI staining (Sigma-Aldrich, St. Louis, Missouri, https://www.sigmaaldrich.com). Sections were then mounted onto the glass slide. Images were acquired on a Zeiss LSM 710 confocal microscope or LSM 7 ELYRA PS.1 system (Carl Zeiss, Pte. Ltd., Singapore, www.zeiss.com.sg).
Immunofluorescence Staining
For immunofluorescence assays, the cells were fixed in 4% paraformaldehyde for 10 minutes. The fixed cells were washed three times with 0.1 M Tris-buffered saline containing 0.1% Triton-X 100 (TBS-TX) and incubated in the following primary antibodies in blocking buffer at 48C overnight: mouse anti-Oct3/4 (1:500, Santa Cruz Biotechnology, Inc. Dallas, Texas, http://www.scbt.com), mouse anti-Tra-1-60 (1:100, Santa Cruz Biotechnology, Inc. Dallas, 4 Targeting Telomerase for Cell Therapy 
RESULTS
Engineering hTERT Knockout ES Cells
Human telomerase contains two core components the protein catalytic subunit, hTERT, and the RNA subunit, hTR [2, 3] .
Deletion of either hTERT or hTR resulted in the complete loss of telomerase activity in vivo as shown in mouse models [24, [46] [47] [48] [49] . First, we used the CRISPR/Cas9 system to inactivate hTERT directly. As shown in Supporting Information Figure  S1A , S1B, five CRISPR guide RNAs targeting hTERT exon 1 were designed, and all resulted in efficient, site-specific double strand breaks (DSBs). To enhance genome-editing specificity, Cas9 nickase was transfected with a pair of CRISPR guide RNAs (S2 and S3) to introduce targeted DSBs [50] illustrated in Supporting Information Figure S1C . Six independent ES cell clones derived from the WA018 ES cell line with a deletion in hTERT exon 1 were isolated using fluorescent PCR-capillary gel electrophoresis [35] . DSB-induced insertion/deletion (indel) mutations in three clones were confirmed by Sanger sequencing (Supporting Information Fig. S1D ). As shown in Supporting Information Fig. S1E , the DSB-induced indels resulted in complete loss of telomerase activity in these three ES cell clones. All three telomerase-null ES cell clones maintained normal karyotype (data not shown). However, these telomerase-null ES cells clones had short median telomeres approximately 5-6 kb (Supporting Information Fig. S1F, lanes 2-4) . They could only be cultured for another 5-6 passages before cell proliferation loss and cell death induction, which is consistent with previous publication [38] . The cell death in these ES cell clones is distinct from primary fibroblasts that enter senescence when telomeres are critically short. The shortened proliferation capacity of telomerase-null ES cells limited their utility to understand ES cell responses to telomere dysfunction. To eliminate the possibility that the reduced proliferation lifespan of telomerase-null WA018 ES cells was due to potential off-target effects of CRISPR/Cas9 system, we engineered telomerase-inducible knockout ES cells in different human ES cell lines (H1) using zinc finger nuclease (ZFN)-mediated gene targeting [34, [51] [52] [53] [54] [55] [56] . Paired ZFNs were engineered to target distinct genomic DNA sequences in exon 1 of hTERT as shown in Supporting Information Figure S2 . The expression of ZFNs in H1 ES cells resulted in site-specific DSBs in hTERT exon 1 with a low cutting efficiency (2%-3%) (Supporting Information Fig. S2B ). So, we utilized ZFNs for gene targeting to create hTERT-inducible knockout human H1 ES cells. Our targeting vector introduced two loxP sites flanking hTERT exon 1 and exon 2 (Fig. 1A) . Cre recombinase expression will result in the deletion of both exon 1 and exon 2 from the hTERT genomic locus, which encompasses almost 50% of the hTERT N-terminal protein coding region. To avoid cutting the targeting vector by coexpressed ZFNs during the gene targeting process, the ZFNs-binding sites on the targeting vector were mutated. These mutations resulted in a dramatic improvement in the stability of the full-length targeting vector (Supporting Information Fig. S3 ). Two rounds of gene targeting were performed to introduce loxP sites flanking both hTERT alleles (Supporting Information Fig. S4 ). The targeted hTERT alleles were confirmed through Southern blotting analysis (Fig. 1B) . As shown by RNA protection assay (Fig. 1C) , deletion of one hTERT copy (hTERT 1/2 ) resulted in a 50% loss of hTERT mRNA expression, while deletion of both hTERT copies (hTERT
) yielded a complete loss of fulllength hTERT mRNA expression in H1 ES cells. Consistent with the hTERT mRNA expression results, deletion of one allele of hTERT yielded an approximate 50% reduction of telomerase activity, and deletion of both alleles of hTERT resulted in a complete loss of telomerase activity (Fig. 1D) as determined by the TRAP assay [4] . Given the propensity of human ES cells to accumulate genetic aberrations during extended culture in vitro, karyotyping was done at each gene-targeting step to verify that the clonal-derived human ES cell lines maintain a normal karyotype (Supporting Information Fig. S5 ).
Stem Cell Marker Expression in Telomerase Knockout ES Cells
Like parental H1 ES cells (hTERT
), the hTERT 1/2 and hTERT 2/2 ES cells expressed ES cell-specific surface antigens [57] , such as TRA-1-60 and SSEA-4, and genes that maintain the undifferentiated ES cell state, such as OCT4 and NANOG ( Fig. 2A-2D ). Using qRT-PCR, expression levels of ES cell marker genes in hTERT 1/2 and hTERT 2/2 ES cells were comparable to parental H1 ES cells (hTERT 1/1 ), although there were small variations in different independent hTERT 1/2 and hTERT 2/2 clonal ES cell lines (Fig. 2E ).
Progressive Telomere Shortening and Cell Proliferation Loss in Telomerase-Null ES Cells
Telomere length in parental H1 ES cells (hTERT 1/1 ) was 13-14 kb determined through genomic Southern blotting analysis ) showed slightly shortened telomeres compared to parental H1 ES cells. This was likely due to the disruption of hTERT expression by the neomycin-resistant gene cassette in the targeting vector (Fig. 1A) during the gene targeting process (Supporting Information Fig. S4 ). Introduction of loxP sites flanking exon 1 and exon 2 of hTERT also potentially inhibited hTERT mRNA expression. Consistent with this, further telomere shortening was observed in ES cell colonies with loxP sites flanking both alleles of hTERT (hTERT loxP/loxP ). As predicted, transient expression of Cre recombinase in hTERT loxP/loxP ES cells resulted in the loss of telomerase activity and gradual shortening of telomere length in hTERT 2/2 ES cells (Supporting Information Fig. 3A, P2-P8 ). Similar to telomerase-null ES cells derived from WA018 ES cell line, the hTERT 2/2 ES cell lines derived from H1 ES cell line could only be cultured for another 8 passages (Fig. 3A) before cell proliferation loss and cell death induction.
Telomere Length Reset in Telomerase Inducible Knockout ES Cells by Transient hTERT Overexpression
Telomere length in hTERT loxP/loxP ES cells was maintained at a short and stable state (5-6 kb) compared to parental H1 ES cells. These data indicate that telomerase activity in hTERT loxP/ loxP ES cells was sufficient for telomere maintenance. These results also suggest that transient hTERT overexpression could boost telomerase activity and reset telomere length in derived from these new hTERT loxP/loxP ES cells also had longer telomeres initially 9-10 kb (Supporting Information Fig. S6 ). Such hTERT 2/2 ES cells could passage much longer than hTERT 2/2 ES cells with short telomeres (Fig. 3A) , which permited an ample supply of telomerase-null ES cells for research and proof-of-principle applications.
Loss of Cell Proliferation Capacity and Increased Cell Death in Late Passage telomerase-Null ES Cells
When primary human fibroblast cells (WI38 PD67) entered a senescent state, cells were permanently arrested at G1 with enlarged cell morphology and positive staining for senescence-associated b-galactosidase as shown in Figure 3C [13, 58] . Similar to senescent primary fibroblast cells, hTERT 2/2 ES cells at late passage also showed increased expression of senescence-associated bgalactosidase activity (Fig. 3D) . Celltiter-Glo luminescent cell viability assay showed that hTERT 2/2 ES cells at early passage (P2 in Fig. 3A ) had similar cell viability and cell proliferation rates compared to hTERT 1/1 and hTERT 1/2 ES cells (Fig. 4A) . As shown in Supporting Information Figure S7A , cellular incorporation of EdU during S phase were comparable in hTERT
, and hTERT 2/2 (P2) ES cells. Cell cycle profile analysis also showed comparable G1, S, and G2/M cell cycle distribution in hTERT 2/2 (P2), hTERT 1/1 , and hTERT 1/2 ES cells (Supporting Information  Fig. S7B ). However, hTERT 2/2 ES cells at late passage (P8 in Fig.  3A ) lost proliferation potential (Fig. 4A) , increased cell population at G1, and decreased cell population at G2/M phase. In addition to cell proliferation loss, Annexin V and 7-AAD staining showed increased apoptosis in hTERT 2/2 (P8) ES cells compared to hTERT 1/1 , hTERT 1/2 , and hTERT 2/2 (P2) ES cells (Fig. 4B) . These results indicate that the cell proliferation capacity of ES cells was limited by telomere length in the absence of telomerase activity. When telomeres become critically short, stem cells lost proliferation capacity and induced apoptosis.
Distinct Stem Cell Responses to Telomere Uncapping and Etoposide Treatment
When telomeres become critically short, chromosomes become uncapped and develop distinct TIFs [10] . As shown in Supporting Information Figure S8, ES cells were treated with 20 lM etoposide, and cellular responses were then compared to hTERT 2/2 ES cells (p8 with dysfunctional telomeres). As shown in Figure 4C (left panels), etoposide treatment resulted in a dramatic increase in ATM (S1981) phosphorylation. In contrast, telomere dysfunction in hTERT 2/2 (P8) ES cells resulted only in a slight increase in ATM (S1981) activation. However, Chk2 priming site (T68) phosphorylation was comparable in hTERT 2/2 (P8) ES cells with dysfunctional telomeres and hTERT 1/1 ES cells treated with 20 lM etoposide for 6 hours. As expected, p53 activation and Puma expression increased, but not p21 expression consistent with ES cells lacking the G1 checkpoint. Dramatic apoptosis induction was comparable in hTERT 2/2 (P8) ES cells with dysfunctional telomeres and hTERT 1/1 ES cells treated with 20 lM etoposide for 4 to 6 hours indicated by increased PARP and Caspase 3 cleavage products (Fig. 4C) . When hTERT 1/1 ES cells were induced to differentiate into NPCs for only three days, the partially differentiated NPCs, confirmed by Nestin expression, were no longer sensitive to etoposide-induced apoptosis demonstrated by the loss of Chk2 (T68) priming site phosphorylation, and PARP and Caspase 3 cleavages (Fig. 4C, right panels) . In contrast, telomere dysfunction in partially differentiated NPCs still resulted in increased Chk2 (T68) priming site phosphorylation, and PARP and Caspase 3 cleavages. These results indicate that partially differentiated NPCs remain sensitive to telomere dysfunction-induced apoptosis, while being resistant to etoposide treatment. These differences are likely due to the irreparable nature of telomere uncapping [11, 12] . These results also indicate that telomere shortening induced by telomerase inactivation in ES cells was effective in eliminating pluripotent stem cells and partially differentiated progenitor cells. This may improve the safety of stem cell therapies, as recent studies also indicated that partially differentiated progenitor cells can spontaneously regain pluripotency [59] .
Genome-Wide Gene Expression Profiling of Telomerase-Null ES Cells
Previous studies found that hTERT has telomere-independent functions crucial for gene expression regulation, which may affect stem cell proliferation and survival [21, 60, 61] . To determine whether hTERT inactivation affects genome-wide gene expression, the gene expression profiles of hTERT 1/1 , hTERT
, hTERT 2/2 (P2), and hTERT 2/2 (P8 with dysfunctional telomeres) ES cells were analyzed by DNA microarray analysis. No significant differences in gene expression were observed in hTERT 1/1 , hTERT 1/2 and hTERT 2/2 (P2) ES cells ( Fig. 5A and Supporting Information Tables S1-S3). As expected, p53 DNA damage response activation and apoptosis induction was readily observed in hTERT 2/2 (P8 with dysfunctional telomeres) ES cells consistent with their telomeres being critically short (Fig. 5B, Supporting Information Fig. S9 and Table S4, S5) . Previous results demonstrated that hTERT loss affects gene expression within Wnt/b-catenin pathway members [62] . However, results from our DNA microarray analysis did not show significant changes in gene expression profile in the Wnt/b-catenin pathway (Supporting Information  Table S6 ). Interestingly, even when apoptosis was induced in late passage telomerase-null ES cells, most pluripotency genes were still expressed at similar levels compared to hTERT
ES cells (Supporting Information Table S7 ).
Telomerase-Null ES Cell Pluripotency
Next, we investigated whether inactivation of telomerase activity affects ES cell pluripotency. Loss of telomerase activity does not affect stem cell marker expression in independent hTERT
, hTERT 1/2 and hTERT 2/2 ES cell lines (Fig. 2) . To determine the differentiation potential of telomerase-null ES cells in vitro, these cells were grown in suspension to induce EBs formation [63] . The hTERT , hTERT 1/2 and hTERT 2/2 ES cells were injected subcutaneously into the dorsal-lateral area of immunodeficient NSG mice as previously described [45] . Eight weeks postinjection, teratoma formation was evaluated (Fig. Fig. 3A) were injected into immunodeficient mice, no injection (0/60) resulted in teratoma formation in vivo. Consistent with these results, hTERT 2/2 ES cells with short telomeres (4 kb; P4 in Fig. 3A) could only be cultured in vitro for another 4 passages. Histological examination of the tumors obtained from hTERT 1/1 , hTERT 1/2 , and hTERT 2/2 ES cells showed that these tumors contained various tissues derived from all three germ layers, including respiratory epithelium (endoderm), striated muscle and cartilage (mesoderm), and neural epithelium with rosettes (ectoderm) (Fig. 5D) . No alternative lengthening of telomere (ALT) pathway activation in teratomas derived from hTERT 2/2 ES cells was observed (Supporting Information Fig.  S11 ). These results indicated that telomerase activity inactivation does not affect ES cell pluripotency. However, the proliferation capacity of hTERT 2/2 ES cells and their ability to form teratomas in vivo is limited by telomere length, which presets their proliferation potential.
Neural Differentiation of telomerase-Null ES Cells In Vitro
We, then, tested whether hTERT 2/2 ES cells can differentiate into specific cell types using established protocols for human ES cell differentiation. Neural induction of hTERT , and hTERT 2/2 ES cells showed similar ability to differentiate into DCX-positive immature neurons, as well as GFAP-positive glial cells (Supporting Information Fig. S12C-S12E ).
Neural Differentiation of telomerase-Null ES Cells In Vivo
NPCs derived from human ES cells and iPS cells hold great promise for an array of neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, and spinal cord injuries. However, injection of NPCs rather than terminally differentiated cells further raises the risk of tumor formation in vivo [64] . To determine whether newly engineered hTERT (Fig. 6E, 6F ). In contrast, no tumors were found in mice that were injected with hTERT 2/2 ES cells (Fig. 6E) Fig. S13 ). The injected hTERT 2/2 ES cells were viable and proliferating (Supporting Information Fig. S14A ). MAP2a-(mature neuronal marker) and tyrosine hydroxylase (TH; a marker for mature dopaminergic neuron)-positive cells differentiated from hTERT 2/2 ES cells were detected 16 weeks after injection (Supporting Information Figure S14B , S14C 
DISCUSSION
The ability of pluripotent stem cells to self-renew and to differentiate into various cell types from all three germ layers provides an unlimited resource for human cell therapy and disease modeling. However, they also proliferate continuously raising concerns for tumor formation in vivo, since pluripotent stem cells share cellular and genetic similarities with cancer cells [65] . These pluripotent stem cells can form teratomas as low as a few hundred when injected into immunodeficient mice [66, 67] . Since oncogenic characteristics of human pluripotent stem cells are so central to their identity, teratoma formation is the gold standard to demonstrate pluripotency of stem cells. There is a similar risk using partially differentiated progenitor cells, since they can regain pluripotency spontaneously [59] . Indeed, recent reports confirm that donor-derived tumors occur after allogeneic neural progenitor stem cell [64] and autologous hematopoietic stem cell transplantations [68] . These reports propose strategy developments to reduce and overcome the tumorigenicity risk of pluripotent stem cells. These strategies entail eliminating residual pluripotent stem cells from differentiated cells and using suicide genes [69] [70] [71] . While these strategies show promise, major limitations still persist. For example, technological challenges exist to completely separate differentiated cells from residual pluripotent stem cells. These methods may not completely eliminate partially differentiated progenitor cells, as DNA damage agents are not effective to purge partially differentiated progenitor cells. Recent clinical trials utilizing suicide genes, such as HSV-TK and FKBP-caspase 9, elicit immunogenicity in patients and incomplete elimination of targeted cells respectively [70, 71] . In addition to these obstacles, cell therapy poses further complications to implement these strategies, since high number of cells (up to hundreds of thousands) may be necessary for each cell therapy. Differentiated cells derived from pluripotent stem cells may also acquire secondary genetic mutations leading to malignant transformations during cell culture in vitro. Prolonged culture of pluripotent stem cells in vitro can produce various genomic abnormalities including chromosomal translocations and aneuploidy, subchromosomal duplication and deletion, and point mutations [72] . Therefore, the technical burden of separating differentiated cells from Our results suggest that inactivation of telomerase activity through hTERT knockout in ES cells limits the self-renewal capacity of stem cells. We further demonstrated that hTERT inactivation does not alter ES cell pluripotency using in vitro and in vivo assays. When telomeres shorten to a critical limit approximately 3-4 kb, ES cells trigger DNA damage response-induced apoptosis. Partially differentiated NPCs are also sensitive to dysfunctional telomeres. This is significant, since these NPCs are resistant to etoposide-induced apoptosis. The irreparable nature of telomere DNA damage [11, 12] may play a role in stimulating NPC apoptosis. Consistent with these results, telomerase-null ES cells also lost the ability to form teratomas in vivo when their telomeres reach approximately 4 kb as measured by teloblot. Since telomere dysfunction is induced by critically short telomeres and individual telomere length in ES cells can be longer or shorter than 4 kb, a more accurate method for telomere length measurement, such as STELA [73] , may be advantageous to select clonal telomerase-null ES cells for in vivo cell therapy in the future. By selecting telomerase-null ES cells with shorter telomere lengths, we can potentially reduce the tumor formation risk for in vivo cell therapy. Telomerase activity is significantly elevated in more than 85%-90% of all human cancers and in over 70% of immortalized human cell lines [4, 74, 75] . Telomerase activity upregulation in cancer cells is necessary for telomere maintenance and continuous cancer cell division. Blocking telomere maintenance through inactivating telomerase activity also reduces the tumorigenicity risk of progenitor cells derived from ES cells that acquired secondary genetic mutations, which may promote hTERT activation and cell immortalization in vivo. Telomere length can be sustained in telomerase-negative cells by activating ALT mechanisms [76] . However, we did not observe any spontaneous emergence of ALT survivors from telomerase-null human ES cells in vitro and in vivo (Supporting Information Fig. S11 ). Additional mutations and factors may be necessary to activate the ALT pathway in telomerase-null human ES cells. Therefore, our results suggest that substantial reductions in tumor formation risk from pluripotent stem cells occur through restricting telomere maintenance mechanisms in vivo.
Given that telomerase expression is naturally silenced during somatic tissue differentiation [4, 74] , telomerase is likely dispensable for normal cellular functions in terminally differentiated cells. This prediction is supported by observations that telomerase knockout mice are viable, fertile, and relatively normal through the first 2-3 generations, due to the extremely long telomeres in laboratory mice [24, [46] [47] [48] [49] . Further, our data indicate that no dramatic differences in cell proliferation and cell viability in hTERT , hTERT 1/2 , and hTERT 2/2 ES cells before telomeres shortened to a critical length (Supporting Information Tables S1-S5 ). For stem cell-based cell transplantation applications using terminally differentiated cells, such as retinal pigment cells and specific progenitor cells, such as NPCs and mesenchymal stem cells, telomerase-null ES cells will be useful as these cells do not require sustained cell proliferation in vivo indicating that they do not need sustained telomerase activity. By tailoring telomere length in telomerase-null ES cells, we can predict and can limit the proliferation capacity of progenitor cells derived from telomerase-null ES cells. Therefore, this strategy provides a solution to balance the capacity of cell proliferation and the prevention of tumor formation.
CONCLUSIONS
This study demonstrates that telomerase is dispensable for ES cell pluripotency. Further, our results provide a potential strategy to improve the safety of cell therapy through telomerase inactivation, which inhibits tumor formation in vivo.
